Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra Van Lint

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal for Immunotherapy of Cancer|November 13, 2021
Selective IL-1 activity on CD8<sup>+</sup> T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradicationBram Van Den Eeckhout, Leander Huyghe, Sandra Van Lint, et al.
Cancer Research|March 2, 2012
Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapyPerpetua U Emeagi, Sandra Van Lint, Cleo Goyvaerts, et al.
Frontiers in Immunology|November 5, 2024
A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screensRamiro Martinez, Chiara Finocchiaro, Louis Delhaye, et al.
Molecular Therapy. Nucleic Acids|November 21, 2013
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In VivoDaphné Benteyn, Sébastien Anguille, Sandra Van Lint, et al.
Cancer Immunology Research|December 15, 2015
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic CellsSandra Van Lint, Dries Renmans, Katrijn Broos, et al.
Oncoimmunology|February 6, 2018
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironmentAnje Cauwels, Sandra Van Lint, Geneviève Garcin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2016
Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell ResponsesAns De Beuckelaer, Charlotte Pollard, Sandra Van Lint, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 3, 2018
Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral ResponsesLutz Nuhn, Stefaan De Koker, Sandra Van Lint, et al.
Molecular Cancer|November 29, 2023
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor stateSandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, et al.
EMBO Molecular Medicine|January 9, 2020
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapiesLeander Huyghe, Alexander Van Parys, Anje Cauwels, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal for Immunotherapy of Cancer|November 13, 2021
Selective IL-1 activity on CD8<sup>+</sup> T cells empowers antitumor immunity and synergizes with neovasculature-targeted TNF for full tumor eradicationBram Van Den Eeckhout, Leander Huyghe, Sandra Van Lint, et al.
Cancer Research|March 2, 2012
Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapyPerpetua U Emeagi, Sandra Van Lint, Cleo Goyvaerts, et al.
Frontiers in Immunology|November 5, 2024
A co-culture model to study modulators of tumor immune evasion through scalable arrayed CRISPR-interference screensRamiro Martinez, Chiara Finocchiaro, Louis Delhaye, et al.
Molecular Therapy. Nucleic Acids|November 21, 2013
Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In VivoDaphné Benteyn, Sébastien Anguille, Sandra Van Lint, et al.
Cancer Immunology Research|December 15, 2015
Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic CellsSandra Van Lint, Dries Renmans, Katrijn Broos, et al.
Oncoimmunology|February 6, 2018
A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironmentAnje Cauwels, Sandra Van Lint, Geneviève Garcin, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|August 11, 2016
Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell ResponsesAns De Beuckelaer, Charlotte Pollard, Sandra Van Lint, et al.
Advanced Materials (Deerfield Beach, Fla.)|October 3, 2018
Nanoparticle-Conjugate TLR7/8 Agonist Localized Immunotherapy Provokes Safe Antitumoral ResponsesLutz Nuhn, Stefaan De Koker, Sandra Van Lint, et al.
Molecular Cancer|November 29, 2023
A bispecific Clec9A-PD-L1 targeted type I interferon profoundly reshapes the tumor microenvironment towards an antitumor stateSandra Van Lint, Alexander Van Parys, Bram Van Den Eeckhout, et al.
EMBO Molecular Medicine|January 9, 2020
Safe eradication of large established tumors using neovasculature-targeted tumor necrosis factor-based therapiesLeander Huyghe, Alexander Van Parys, Anje Cauwels, et al.
Pageof 4